OliX Pharmaceuticals올릭스
226950 · KOSDAQ · ₩226950 · 올릭스
₩96,100▼ ₩7,200 (6.97%)End-of-day · Oct 26, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | — | — | — | 100.0% | 100.0% | — |
| Operating margin | −304.7% | −204.4% | −544.6% | −106.6% | −240.1% | −691.9% |
| Net margin | −102.9% | −107.3% | −716.2% | −111.9% | −209.2% | −808.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −7.0% | +158.3% | −66.7% | +83.1% | +153.7% | — |
| Operating income growth | −38.6% | +3.1% | −70.0% | +18.7% | +12.0% | — |
| Net income growth | +10.9% | +61.3% | −112.9% | +2.0% | +34.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −7.3% | −18.8% | −120.1% | −33.0% | −46.2% | −160.4% |
| Return on assets | −7.5% | −11.8% | −46.7% | −16.2% | −20.0% | −34.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 15.4% | 30.2% | 285.7% | 104.3% | 100.4% | 346.6% |
| Net debt to equity | −72.0% | −50.8% | 187.1% | 26.6% | 51.8% | 10.7% |
| Current ratio | 1,173.7% | 660.5% | 51.7% | 489.7% | 164.5% | 129.4% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: OliX Pharmaceuticals / 올릭스 / 226950 / KRX:226950
Source: KRX statistical information